BioCentury | Nov 11, 2020
Emerging Company Profile

CatalYm: opening up tumors to immune cells

...Growth differentiation factor 15GFRAL – GDNF family receptor alpha likeICAM-1 (CD54) – Intercellular adhesion molecule-1LFA-1 (CD11a-CD18)PD-1...
BioCentury | Sep 1, 2020
Politics, Policy & Law

Proposed CMS pathway could be expanded to give therapies, diagnostics immediate, national coverage

A medical devices reimbursement rule proposed by CMS could lay the groundwork for innovative medicines to be covered by Medicare immediately after FDA approval. The proposed rule, which applies only to...
BioCentury | Aug 28, 2020
Deals

BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration

...a small molecule activator of VLA-4 and CD11a-CD18...
...detection and recovery surveillance. TARGETSCas13d – CRISPR-associated protein 13dCD11a-CD18...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Preventing thrombosis using nanoparticles loaded with anti-G protein peptides

...peptide core with a sequence derived from GPIIIa’s...
...protein alpha 13 (GNA13); integrin β3 (GPIIIa; CD61...
...of Illinois at Chicago G protein alpha 13 (GNA13) Integrin beta(3) (GPIIIa) (CD61) Cardiovascular Ischemia/reperfusion...
BioCentury | Jun 3, 2020
Finance

Third Rock-launched Pliant is latest biotech to climb on public debut

...CD51 (CD29) - Integrin α(V)β(1) Danielle Kopke, Staff Writer PLN-1474 PLN-74809 Pliant Therapeutics Inc. Novartis AG Third Rock Ventures Citigroup Cowen Piper Sandler Needham Integrin alpha(V)beta(1) (CD51/CD29) Integrin...
BioCentury | Jun 2, 2020
Finance

CAR T play Legend looks to lead trio of biotechs onto NASDAQ

...Swedish company in any sector in 15 years to list on the exchange. Targets CD51 (CD29...
BioCentury | May 11, 2020
Finance

Third Rock-backed fibrosis company Pliant joins IPO queue

...$125 million at a valuation of $1.1 billion (see “ADC Renews Bid” ). Targets CD51 (CD29...
BioCentury | Mar 3, 2020
Finance

Pliant to advance rare fibrosis pipeline with Novartis-led $100M C round

...royalties (see "Pliant to Flesh Out Fibrosis Pipeline After NASH Deal" ). PLN-74809, a dual CD51/CD29...
...CD51/CD29 - Integrin α V β 1 Sandi Wong, Assistant Editor Pliant Therapeutics Inc. Novartis AG Integrin alpha(V)beta(6) Integrin alpha(V)beta(1) (CD51/CD29) idiopathic...
BioCentury | Feb 4, 2020
Product Development

Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

Insmed rose $8.34 (41%) to $28.88 on Monday, gaining $745 million in market cap, after its chronic lung inflammation therapy met the primary endpoint in a Phase II study. But the data, which included an...
BioCentury | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

...Two subsets -- one positive and one negative for FAP, and both expressing ACTA2 and CD29...
...2 smooth aorta muscle; BCMA (TNFRSF17; CD269) - Tumor necrosis factor receptor superfamily member 17; CD29...
...β BioCentury Staff TeneoBio Inc. Institut Curie Institut National de la Sante et de la Recherche Medicale (INSERM) NIH Basilea Pharmaceutica Ltd. Integrin beta(1) (CD29) Tumor...
Items per page:
1 - 10 of 377